Gefitinib improves survival compared with standard chemotherapy in lung cancer patients with genetic mutation
Sunday, December 20, 2009 - 18:35
in Health & Medicine
Patients with the most common form of lung cancer (non-small-cell lung cancer) who have mutations in the epidermal growth factor receptor (EGFR) gene have significantly improved progression-free survival if they are treated with gefitinib compared with standard chemotherapy. Wherever possible, EGFR genetic testing must be done and gefitinib should be considered as the first-line treatment for patients with EGRF mutations, concludes an Article published Online First in The Lancet Oncology.